Black Diamond Therapeutics News

Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.

Black Diamond Theraptcs Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 16 07:46 ET

Black Diamond Therapeutic Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 100% HC Wainwright & Co. $12 → $11 Maintains Buy 04/08/2024 190.91% Wedbush $10 → $16 Maintains

BenzingaMay 16 07:35 ET

Buy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical Trials

TipRanksMay 16 06:30 ET

Express News | Black Diamond Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $11 From $12

ReutersMay 16 06:09 ET

Express News | Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025

BenzingaMay 9 08:12 ET

Express News | Black Diamond Therapeutics Inc: Cash, Cash Equivalents, and Investments of $115.2 Mln as of March 31, 2024

ReutersMay 9 07:36 ET

Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX

Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX

Dow JonesMay 9 07:32 ET

Express News | Black Diamond Therapeutics Q1 Income From Operations USD -20.246 Million

ReutersMay 9 07:30 ET

Express News | Black Diamond Therapeutics Q1 Basic EPS USD -0.35

ReutersMay 9 07:30 ET

Express News | Black Diamond Therapeutics Q1 Operating Expenses USD 20.246 Million

ReutersMay 9 07:30 ET

Express News | Black Diamond Therapeutics Q1 Net Income USD -18.225 Million

ReutersMay 9 07:30 ET

Press Release: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024

Dow JonesMay 9 07:30 ET

Black Diamond Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 07:17 ET · Announcements

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

PDF Version Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; ini

Black Diamond TherapeuticsMay 9 00:00 ET

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

PDF Version CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fa

Black Diamond TherapeuticsApr 24 00:00 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS

BenzingaApr 23 16:31 ET

Garry Menzel Joins GHO Capital as Operating Partner

Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering

GlobeNewswireApr 23 07:45 ET

Black Diamond Therapeutics Announces Changes to Board of Directors

PDF Version CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fa

Black Diamond TherapeuticsApr 11 00:00 ET

Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler

TipRanksApr 9 07:07 ET

Black Diamond Theraptcs Is Maintained at Outperform by Wedbush

Black Diamond Theraptcs Is Maintained at Outperform by Wedbush

Dow JonesApr 8 11:29 ET